APA

Lee J. D., Nunes E. V., Novo P., Bachrach K., Bailey G. L., Bhatt S., Farkas S., Fishman M., Gauthier P., Hodgkins C. C., King J., Lindblad R., Liu D., Matthews A. G., May J., Peavy K. M., Ross S., Salazar D., Schkolnik P., Shmueli-Blumberg D., Stablein D., Subramaniam G. & Rotrosen J. (20180409). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. : Lancet (London, England).

Chicago

Lee Joshua D, Nunes Edward V, Novo Patricia, Bachrach Ken, Bailey Genie L, Bhatt Snehal, Farkas Sarah, Fishman Marc, Gauthier Phoebe, Hodgkins Candace C, King Jacquie, Lindblad Robert, Liu David, Matthews Abigail G, May Jeanine, Peavy K Michelle, Ross Stephen, Salazar Dagmar, Schkolnik Paul, Shmueli-Blumberg Dikla, Stablein Don, Subramaniam Geetha and Rotrosen John. 20180409. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. : Lancet (London, England).

Harvard

Lee J. D., Nunes E. V., Novo P., Bachrach K., Bailey G. L., Bhatt S., Farkas S., Fishman M., Gauthier P., Hodgkins C. C., King J., Lindblad R., Liu D., Matthews A. G., May J., Peavy K. M., Ross S., Salazar D., Schkolnik P., Shmueli-Blumberg D., Stablein D., Subramaniam G. and Rotrosen J. (20180409). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. : Lancet (London, England).

MLA

Lee Joshua D, Nunes Edward V, Novo Patricia, Bachrach Ken, Bailey Genie L, Bhatt Snehal, Farkas Sarah, Fishman Marc, Gauthier Phoebe, Hodgkins Candace C, King Jacquie, Lindblad Robert, Liu David, Matthews Abigail G, May Jeanine, Peavy K Michelle, Ross Stephen, Salazar Dagmar, Schkolnik Paul, Shmueli-Blumberg Dikla, Stablein Don, Subramaniam Geetha and Rotrosen John. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. : Lancet (London, England). 20180409.